Cargando…
Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498220/ https://www.ncbi.nlm.nih.gov/pubmed/32964210 http://dx.doi.org/10.1016/S2665-9913(20)30333-7 |
| _version_ | 1783583463670022144 |
|---|---|
| author | Guaraldi, Giovanni Milic, Jovana Cozzi-Lepri, Alessandro Pea, Federico Mussini, Cristina |
| author_facet | Guaraldi, Giovanni Milic, Jovana Cozzi-Lepri, Alessandro Pea, Federico Mussini, Cristina |
| author_sort | Guaraldi, Giovanni |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7498220 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74982202020-09-18 Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply Guaraldi, Giovanni Milic, Jovana Cozzi-Lepri, Alessandro Pea, Federico Mussini, Cristina Lancet Rheumatol Correspondence Elsevier Ltd. 2020-12 2020-09-17 /pmc/articles/PMC7498220/ /pubmed/32964210 http://dx.doi.org/10.1016/S2665-9913(20)30333-7 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Guaraldi, Giovanni Milic, Jovana Cozzi-Lepri, Alessandro Pea, Federico Mussini, Cristina Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply |
| title | Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply |
| title_full | Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply |
| title_fullStr | Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply |
| title_full_unstemmed | Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply |
| title_short | Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply |
| title_sort | tocilizumab in covid-19: finding the optimal route and dose – authors' reply |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498220/ https://www.ncbi.nlm.nih.gov/pubmed/32964210 http://dx.doi.org/10.1016/S2665-9913(20)30333-7 |
| work_keys_str_mv | AT guaraldigiovanni tocilizumabincovid19findingtheoptimalrouteanddoseauthorsreply AT milicjovana tocilizumabincovid19findingtheoptimalrouteanddoseauthorsreply AT cozzileprialessandro tocilizumabincovid19findingtheoptimalrouteanddoseauthorsreply AT peafederico tocilizumabincovid19findingtheoptimalrouteanddoseauthorsreply AT mussinicristina tocilizumabincovid19findingtheoptimalrouteanddoseauthorsreply |